LOS ANGELES, May 26, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Blueprint Medicines Corporation (“Blueprint” or “the Company”) (NASDAQ: BPMC) for potential breaches of fiduciary duty on the part of its directors and management.
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) traded at a new 52-week high today and are currently trading at $90.05. So far today, approximately 436.14k shares have been exchanged, as compared to an average 30-day volume of 872.33k shares.
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties.
San Diego, CA -- (SBWIRE) -- 08/30/2022 -- Blueprint Medicines Corporation is under investigation over potential securities laws violations in connection with certain financial statements.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or “the Company”) (NASDAQ: BPMC) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or “the Company”) (NASDAQ: BPMC) for violations of the securities laws.
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.
